Containment Drug Delivery Systems FDA Approval 
XTalks
JULY 26, 2024
These issues primarily stem from patients and healthcare providers miscalculating or incorrectly administering the drug. Compounded semaglutide products, unlike the US Food and Drug Administration (FDA)-approved ones, can vary widely in strength and packaging, making it easy for mistakes to happen.
FDA Law Blog
JUNE 13, 2024
FTC, deep in its foray into the Orange Book, filed an Amicus Brief in the case arguing that the patents do not claim any FDA-approved drug.
FDA Law Blog
MARCH 12, 2024
It’s difficult to conclude from these statements, as FTC and Congress appear to have, that device patents categorically shouldn’t be listed in the Orange Book.
Expert insights. Personalized for you.
91 
Let's personalize your content